Skip to content

Capricor Therapeutics CAPR Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-56.4%-46.6%-107.8%
Return on assets-47.7%+6.5pp-39.9%-4.6pp-74.7%-22.3pp-81.4%-15.1pp-54.2%-7.1pp
Return on invested capital-83.2%-128.7%-206.8%
Liquidity
Current ratio8.4×+1.9×+1.2×3.6×-0.6×4.4×+3.0×6.5×+5.0×
Quick ratio8.4×+1.9×+1.2×3.6×-0.6×4.4×+3.0×6.5×+5.0×
Cash ratio3.1×+1.8×+7.5×0.7×-2.6×0.8×+0.3×1.3×+1.1×
Leverage
Debt-to-equity0.1×0.0×0.0×0.2×+0.1×
Debt-to-assets0.0×0.0×0.1×+0.1×-0.1×-0.1×
Per Share
Book value per share$4.85+73.5%$6.58+59.3%$1.83-11.1%$2.30+536%$2.80+376%
Valuation
Market capitalization$1.75B+303%$1.57B+150%$329.62M-38.7%$422.8M+177%$433.47M+103%
Enterprise value$1.66B+308%$1.3B+110%$324.65M-31.5%$400.6M+172%$405.92M+91.1%
Price / book6.3×+2.9×5.1×+0.8×3.9×-3.9×3.4×
Free cash flow yield-5.7%+5.0pp-4.6%+1.9pp-19%-12.0pp-12.9%-10.8%
Earnings yield-6.6%+6.1pp-6.7%-0.2pp-24.9%-18.5pp-16.6%+1.8pp-12.7%-1.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Capricor Therapeutics's ratios come from?
Every ratio is computed from Capricor Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.